TOKYO, Japan (ots) – Auf der internationalen Consumer Electronics Show 2012 (CES) wird Renesas Mobile Corporation, ein führender Anbieter von hochmodernen Plattformen für den Mobilfunk, eine Reihe innovativer Lösungen demonstrieren. Die Neuheiten wurden entwickelt, um der Verbreitung von Geräten für das LTE-Netz (Long Term Evolution) neue Dynamik zu verleihen. Damit werden schneller als bisher geplant [...]
Tag Archive > Tokyo Japan
Helsinn and Taiho Pharmaceutical Co., Ltd. to Extend Relationship / License Agreement for Japan on Potential New Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV)
Lugano, Switzerland and Tokyo, Japan (ots) – Helsinn Group of Switzerland and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn’s second generation 5-HT3 receptor antagonist palonosetron, announce today the signing on April 12, of a licensing agreement granting Taiho the development and commercialization rights for a new product for potential use in the prevention of [...]
Astellas Enters Into License Agreement With TOLMAR
Tokyo (ots/PRNewswire) – Astellas Pharma Inc. announced today that its European subsidiary Astellas Pharma Europe Ltd.(“Astellas Pharma Europe”, headquarters: Stains, U.K.)” acquired the license for commercialization of the treatment for advanced prostate cancer Eligard(R) from TOLMAR Inc. (“TOLMAR”, headquarters: Colorado, U.S.A.) on December 22, 2010 in a selection of Asian, Middle Eastern, North African and [...]
Liquent gibt strategische Partnerschaft mit eSA, Inc. bekannt
Horsham, Pennsylvania (ots/PRNewswire) – Liquent, Inc. gab heute bekannt, dass sie eine strategische Partnerschaft mit eSA, Inc., einem führenden Anbieter von Lösungen für regulatorisches Informations-Management und aufsichtsrechtliche Dienstleistungen in Asien, geschlossen hat. Durch einen Exklusivvertrag hat eSA jetzt die Verantwortung für den kommerziellen und technischen Support für Liquent’s strategische Angebote, Liquent InSight und Liquent SmartDesk. [...]
Hoya Announces First Quarter Financial Results
Tokyo, August 3, 2010 (ots/PRNewswire) – HOYA Corporation today announced financial results for the first quarter ended June 30, 2010. Net sales were 105.5 billion yen for the quarter, a 11.2% increase from 94.9 billion yen in the same period last year, and operating income was 20.1 billion yen, a 116.6% increase from 9.2 billion [...]
Medivation und Astellas geben bekannt, dass in the Lancet die positiven ergebnisse aus der studie der phase 1-2 zur verwendung von MDV3100 bei patienten mit fortgeschrittenem Prostatakrebs veröffentlicht werden
SAN FRANCISCO, Kalifornien und TOKYO, Japan, April 15, 2010 (ots/PRNewswire) — Medivation, Inc. und Astellas Pharma Inc. haben heute bekannt gegeben, dass in der Online-Version der Zeitschrift The Lancet vom 15.April 2010 positive Resultate aus der vor kurzem gemeldeten Studie der Phase 1-2 zur Verwendung des neuen dreifach aktiven oralen Androgenrezeptor- Antagonisten MDV3100 bei Männern [...]
PV Expo: Germany Drives High-Quality Solar Market
Berlin (ots) – Germany is home to approximately every second solar module worldwide, based on industry estimates. 2009 installations exceeded expectations, largely driven by an ongoing demand for high-quality rooftop modules. Germany Trade & Invest will be presenting the latest opportunities available in the world’s largest solar market at this year’s PV Expo, taking place [...]
Hoya Announces Third Quarter Financial Results
Tokyo (ots/PRNewswire) – Hoya Corporation today announced financial results for the third quarter ended December 31, 2009. Net sales were 106.8 billion yen for the quarter, a 5.2% decrease from 112.7 billion yen in the same period last year. Operating income was 18.9 billion yen, a 13.8% increase from 16.6 billion yen in the same [...]
Neuer Geschäftsführer für Hoya Vision Care Europe
Uithoorn, Die Niederlande (ots/PRNewswire) – Hoya gibt die Ernennung von Hans Werquin (49) zum Geschäftsführer von Hoya Vision Care Europe ab 1. April 2010 bekannt. Er wird Gerald W. Bottero unterstellt sein, der den europäischen Zweig des Unternehmens in den vergangenen fünf Jahren geleitet hat. Bottero bleibt weiterhin Präsident von Hoya Vision Care. Werquin kann [...]
Daiichi Sankyo initiates largest single, double-blind, randomized, Phase III trial for treatment and prevention of recurrent venous thromboembolism
Tokyo, Japan and Edison, N.J. (ots) – First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, [...]
NTT Com secures 78 percent of Integralis shares
(pressebox) TOKYO, JAPAN and ISMANING, GERMANY, 19.10.2009, NTT Communications Corporation (NTT Com) is pleased to announce that at the end of the mandatory acceptance period under the German Securities Acquisition and Takeover Act, ended on 14 October 2009, NTT Com has secured further 45,357 shares in Integralis, amounting to approximately 0.4 percent of 11,175,032 Integralis [...]
Philips Chief Medical Officer calls for greater patientempowerment in facing future healthcare challenges
(pressebox) Tokyo,Japan, 16.09.2009, In a keynote speech delivered today at this year’s Nikkei-Philips symposium on "Independent Living and Home healthcare", Dr. Eric Silfen, Chief Medical Officer, Philips Healthcare, reconfirmed Philips’ commitment to ensuring sound and sustainable healthcare in the future. Speaking to an audience of experts from a wide variety of fields and sectors (including [...]
The European Commission Approves Samsca(TM) (tolvaptan), Europe’s First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Tokyo, Japan and Uxbridge, England (ots/PRNewswire) – Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced today that the European Commission has approved the Marketing Authorisation Application for the company’s oral once-daily medication Samsca(TM)(tolvaptan), a selective V2-vasopressin receptor antagonist, for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) [...]
NTT Communications publishes offer document for the takeover of Integralis-Acceptance period begins
(pressebox) TOKYO, JAPAN and ISMANING. GERMANY, 30.07.2009, . – BaFin gives permission for offer document – Acceptance period runs from July 30, 2009 until September 11, 2009 – Offer price of EUR 6.75 per Integralis share – Irrevocable undertakings already secured for approximately 43 percent of Integralis share capital1 NTT Communications Deutschland GmbH, a wholly-owned [...]
NTT Communications announces agreed takeover offer in cash for Integralis AG
(pressebox) TOKYO, JAPAN / ISMANING, GERMANY, 30.06.2009, . – Business Combination Agreement signed – Offer price of 6.75 Euro per Integralis AG share represents a significant premium – Acquisition enables NTT Communications to enhance its global managed security service offering through a market-leading security services platform – Integralis to become lead unit for global IT [...]
